MGRX MANGOCEUTICALS, INC.

Nasdaq www.mangorx.com


$ 2.43 $ -0.03 (-1.22 %)    

Friday, 17-Oct-2025 12:22:51 EDT
QQQ $ 601.20 $ 3.62 (0.61 %)
DIA $ 460.36 $ 1.13 (0.25 %)
SPY $ 661.33 $ 1.86 (0.28 %)
TLT $ 91.12 $ -0.11 (-0.12 %)
GLD $ 386.64 $ -10.55 (-2.66 %)
$ 2.46
$ 2.45
$ 2.40 x 150
$ 2.50 x 200
$ 2.37 - $ 2.45
$ 1.32 - $ 6.15
219,012
na
25.92M
$ -1.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 10-27-2023 09-30-2023 10-Q
9 07-28-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mangoceuticals-q2-eps-057-up-from-135-yoy-sales-168109k-up-from-163163k-yoy

Mangoceuticals (NASDAQ:MGRX) reported quarterly losses of $(0.57) per share. This is a 57.78 percent increase over losses of $(...

 mangoceuticals-entered-into-mutual-rescission-and-release-agreement-with-navy-wharf-to-terminate-and-rescind-msa

-SEC Filing

 mangoceuticals-files-for-mixed-shelf-of-up-to-150m

-SEC Filing

 mangoceuticals-files-for-resale-up-to-45m-shares-of-common-stock-by-selling-shareholders

 - SEC Filing 

 mangoceuticals-entered-into-master-distribution-agreements-to-secure-exclusive-licensing-and-distribution-rights-for-diabetinol-within-us-and-canada

Diabetinol® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss...

 mangoceuticals-announces-advancement-in-avian-flu-prevention-with-water-based-antiviral-for-poultry-using-patented-technology-from-intramont-efficacy-demonstrated-in-phase-i-animal-studies-now-entering-phase-ii

Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, market...

 mangoceuticals-announces-exclusive-distribution-agreement-with-propre-energie-for-dermytol-plant-based-skincare-proven-to-address-hyperpigmentation-and-acne-scars

Mangoceuticals, Inc. (NASDAQ:MGRX), a company focused on developing, marketing, and selling a variety of men's wellness pro...

 mangoceuticals-regains-full-compliance-with-nasdaq-minimum-bid-price-requirement

Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, an...

 mangorx-announces-that-it-has-initiated-a-process-to-evaluate-potential-strategic-alternatives-with-the-intent-to-unlock-and-maximize-shareholder-value-including-but-not-limited-to-potential-mergers-acquisitions-divestitures-and-business-combinations-acquisitions-of-businesses-entry-into-new-lines-of-business-business-expansions-joint-ventures-and-other-key-strategic-transactions-outside-the-ordinary-course-of-the-companys-current-business

Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, an...

Core News & Articles

MangoRx strongly refutes any and all claims made by Eli Lilly regarding the sale of compounded tirzepatide. MangoRx believes it...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION